Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 3/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.43 |
| ▸ | CDK9 | P50750 | 3/20 | 0.43 |
| ▸ | QDPR | P09417 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758301 | 0.80 | HTR6 (0.44) | HTR6HTR2CHTR7CCNT1CDK9 | |
| SCHEMBL7864911 | 0.80 | SIGMAR1 (0.51) | HTR6MAPTHTR2CHTR7CCNT1 | |
| SCHEMBL8599586 | 0.80 | NPC1 (0.48) | CYP1A2CYP3A4MEN1ALDH1A1MAPT | |
| SCHEMBL7859769 | 0.79 | HTR6 (0.37) | HTR6HTR2CQDPR | |
| SCHEMBL6836981 | 0.78 | NPC1 (0.53) | CYP1A2CYP3A4MEN1ALDH1A1MAPT | |
| SCHEMBL4359750 | 0.77 | SIGMAR1 (0.50) | KDM4EALDH1A1MAPTHTR2CHSD17B10 | |
| SCHEMBL8600782 | 0.77 | NPC1 (0.52) | CYP1A2CYP3A4ALDH1A1MAPTCA2 | |
| SCHEMBL8601702 | 0.77 | NPC1 (0.52) | CYP1A2CYP3A4ALDH1A1MAPTCA2 | |
| SCHEMBL8600780 | 0.77 | NPC1 (0.52) | CYP1A2CYP3A4ALDH1A1MAPTCA2 | |
| SCHEMBL8601704 | 0.77 | NPC1 (0.52) | CYP1A2CYP3A4ALDH1A1MAPTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119499181-A | Bortezomib encapsulating agent, bortezomib liposome and preparation method | 浙江海昶生物医药技术有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119499181-A | Bortezomib encapsulating agent, bortezomib liposome and preparation method | 浙江海昶生物医药技术有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-108359654-A | A kind of mutant and its application with phospholipase B activity | 江苏中酶生物科技有限公司 | 2018-08-03 | — | — | CN | disclosed |
| EP-3265063-A1 | DUAL LOADED LIPOSOMAL PHARMACEUTICAL FORMULATIONS | Cureport, Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20050123593-A1 | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints | THOMPSON JONATHAN (GB) | 2005-06-09 | — | — | US | disclosed |
| US-6844344-B2 | Benzofuran derivatives | ELI LILLY AND COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-20030232833-A1 | Benzofuran derivatives | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003017978-A1 | METHOD OF MANUFACTURING LIPOSOMES | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20020119188-A1 | Method of manufacturing liposomes | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020001613-A1 | Method of manufacturing liposomes | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119188-A1 | Method of manufacturing liposomes | LIPA, CLPTM1L, MGLL | HTR6 2652/4885CYP1A2 3944/4885CYP3A4 3678/4885 |
| US-20030232833-A1 | Benzofuran derivatives | BRD1, BPTF, HTR1F | HTR6 38/4885CYP1A2 162/4885CYP3A4 271/4885 |
| US-20020001613-A1 | Method of manufacturing liposomes | LIPA, CLPTM1L, SGMS1 | HTR6 3755/4885CYP1A2 4236/4885CYP3A4 3626/4885 |
| US-20050123593-A1 | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints | CD44, LPCAT1, MMP7 | HTR6 233/4885CYP1A2 3580/4885CYP3A4 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.